These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 26723976)

  • 21. Dose-dependent biochemical changes in rat central nervous system after 12-week exposure to 1-bromopropane.
    Wang H; Ichihara G; Ito H; Kato K; Kitoh J; Yamada T; Yu X; Tsuboi S; Moriyama Y; Takeuchi Y
    Neurotoxicology; 2003 Mar; 24(2):199-206. PubMed ID: 12606292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors.
    Ridoux L; Sémiond DR; Vincent C; Fontaine H; Mauriac C; Sanderink GJ; Oprea C; Kelly L; Clive S
    Anticancer Drugs; 2015 Mar; 26(3):350-8. PubMed ID: 25462133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological evaluation of novel cabazitaxel analogues.
    Ren S; Zhang M; Wang Y; Guo J; Wang J; Li Y; Ding N
    Bioorg Med Chem; 2021 Jul; 41():116224. PubMed ID: 34058663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
    Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cabazitaxel for the treatment of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sartor O
    Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
    Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
    Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose intensity and toxicity associated with Taxotere formulation: a retrospective study in a population of breast cancer patients treated with docetaxel as an adjuvant or neoadjuvant chemotherapy.
    Chanat C; Delbaldo C; Denis J; Bocaccio F; Cojean-Zelek I; Le Guyader N
    Anticancer Drugs; 2015 Oct; 26(9):984-9. PubMed ID: 26237498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro.
    Oprea-Lager DE; Bijnsdorp IV; VAN Moorselaar RJ; VAN DEN Eertwegh AJ; Hoekstra OS; Geldof AA
    Anticancer Res; 2013 Feb; 33(2):387-91. PubMed ID: 23393328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cabazitaxel for the treatment of prostate cancer.
    Michielsen DP; Braeckman JG; Denis L
    Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy-based treatment for castration-resistant prostate cancer.
    Seruga B; Tannock IF
    J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
    Petrylak DP
    Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.
    Wissing MD; van Oort IM; Gerritsen WR; van den Eertwegh AJ; Coenen JL; Bergman AM; Gelderblom H
    Clin Genitourin Cancer; 2013 Sep; 11(3):238-250.e1. PubMed ID: 23659772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ameliorative effect of selenium in cisplatin-induced testicular damage in rats.
    Simsek N; Koc A; Karadeniz A; Yildirim ME; Celik HT; Sari E; Kara A
    Acta Histochem; 2016 Apr; 118(3):263-70. PubMed ID: 26920108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Serum Albumin Nanoparticles as a Novel Delivery System for Cabazitaxel.
    Zhou G; Jin X; Zhu P; Yao JU; Zhang Y; Teng L; Lee RJ; Zhang X; Hong W
    Anticancer Res; 2016 Apr; 36(4):1649-56. PubMed ID: 27069142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.
    Schutz FA; Buzaid AC; Sartor O
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):248-56. PubMed ID: 24613528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concentration rather than dose defines the local brain toxicity of agents that are effectively distributed by convection-enhanced delivery.
    Zhang R; Saito R; Mano Y; Kanamori M; Sonoda Y; Kumabe T; Tominaga T
    J Neurosci Methods; 2014 Jan; 222():131-7. PubMed ID: 24269253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
    Sarantopoulos J; Mita AC; Wade JL; Morris JC; Rixe O; Mita MM; Dedieu JF; Wack C; Kassalow L; Lockhart AC
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1113-24. PubMed ID: 25307552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Cabazitaxel in Renal Cell Carcinoma Cell Lines.
    Mizutani K; Tomoda M; Ohno Y; Hayashi H; Fujita Y; Kawakami K; Kameyama K; Kato T; Sugiyama T; Itoh Y; Ito M; Deguchi T
    Anticancer Res; 2015 Dec; 35(12):6671-7. PubMed ID: 26637883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.